Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00344786
Status:
TERMINATED
Last Update Posted:
2009-06-05
First Post:
2006-06-23
Brief Title:
Phase 1 Dose-Escalation Study of Oral CNF2024BIIB021 in CLL
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia CLL
Status:
TERMINATED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsors decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CLL dosing escalating study daily dosing schedule PKPD safety
Detailed Description:
Phase 1 open-label accelerated-titration study designed to evaluate the effects of increasing doses of CNF2024 on safety pharmacokinetics pharmacodynamic markers and hematological response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 120CL101 | None | None | None |